Last $47.35 USD
Change Today -0.11 / -0.23%
Volume 3.7M
As of 8:04 PM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - $56.73
52 Week Low
08/8/14 - $46.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

glaxosmithkline plc-spon adr (GSK) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

Founded in 1935

glaxosmithkline plc-spon adr (GSK) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GSK) Key Developments

Investors Reportedly Eyes Stake In InterMune

Sanofi SA-(Sanofi AG) and Roche Holding AG (SWX:ROG) are the bidders to acquire InterMune, Inc. (NasdaqGS:ITMN), people with knowledge of the matter said. Also bidding for InterMune are GlaxoSmithKline plc (LSE:GSK) and Actelion Ltd. (SWX:ATLN), said the people, asking not to be identified because the process is private. Sanofi has so far shown the most interest in a deal, one person said. Goldman Sachs Group Inc. and Centerview Partners LLC are helping InterMune sort through bids for the business, the people said. Representatives for InterMune, Sanofi (SAN), Actelion, Roche, GlaxoSmithKline, and Goldman Sachs declined to comment. Representatives for Centerview couldn’t be reached. Shares of InterMune went up by 14% to $52.06.

Private Equity Groups Reportedly Plan Merger Of GlaxoSmithKline And Sanofi Brands

Kohlberg Kravis Roberts & Co. (NYSE:KKR) and Warburg Pincus LLC are among the private equity groups that are exploring a $10 billion plan to acquire hundreds of older drug brands from GlaxoSmithKline plc (LSE:GSK) and Sanofi (ENXTPA:SAN) and merge them, several people familiar with the matter said. GSK had received “very significant” indicative bids from private equity companies and midsized drug makers in a portfolio of mature products with annual sales of about £1 billion. Sanofi is alos looking at divesting about 200 older drugs with annual revenues of at least €2.1 billion. Other private equity groups to have expressed interest in one or both of the portfolios include The Blackstone Group, Private Equity Group, Advent International Corporation, Apollo Global Management, LLC (NYSE:APO) and Bain Capital Ventures, said people close to the matter. The people added that the concept of rolling the two sets of assets together is still at an early stage as Sanofi is yet to make a firm decision on what to do with its portfolio. However, work is being done by potential bidders on a potential combination, those people stated. Mylan, Inc. (NasdaqGS:MYL) and Lupin Limited (BSE:500257) are among potential trade buyers to have been linked with one or both of the GSK and Sanofi businesses. GSK and Sanofi are being advised by Lazard and Evercore respectively.

GlaxoSmithKline plc and Genmab A/S Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

GlaxoSmithKline plc and Genmab A/S announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG (OMB 112517), reached the predefined significance level for efficacy (p<=0.001). The interim analysis demonstrated that treatment with ofatumumab (Arzerra(tm)) met the primary endpoint of improving progression free survival (PFS). The study evaluated ofatumumab maintenance therapy versus no further treatment (observation) in patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse. The IDMC did not identify any new safety signals and will continue to monitor patients for safety until all study patients complete therapy. Further analysis of the safety and efficacy data is underway and will be shared with regulators and the scientific community in the coming months. This pivotal Phase III study was designed to randomize up to 532 patients with relapsed CLL who have responded to treatment at relapse, to either ofatumumab maintenance treatment or no further treatment (observation). Patients in the ofatumumab arm receive an initial dose of 300 mg of ofatumumab, followed one week later by a second dose of 1,000 mg, then doses of 1,000 mg every 8 weeks for up to two years, while patients in the observation treatment arm receive no further treatment. The primary endpoint of the study is PFS. Secondary objectives will evaluate clinical benefit, safety, tolerability, the health-related quality of life of subjects treated with ofatumumab versus no further treatment, and pharmacokinetics among relapsed CLL patients receiving maintenance therapy with ofatumumab. Ofatumumab--a monoclonal antibody that is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes--is not approved or licensed anywhere in the world as maintenance treatment for relapsed CLL. the USA, ofatumumab is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the EU, ofatumumab is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. Ofatumumab is also approved for first-line use in Russia. Ofatumumab is being developed under a co-development and collaboration agreement between Genmab and GSK. Ofatumumab has been associated with infusion reactions. These reactions may result in temporary interruption or withdrawal of treatment or death. Pre-medications attenuate infusion reactions but these may still occur, predominantly during the first infusion. Infusion reactions may include, but are not limited to, anaphylactic reactions, bronchospasm, cardiac events (eg myocardial ischemia /infarction, bradycardia), chills/rigors, cough, cytokine release syndrome, diarrhea, dyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary edema, pruritus, pyrexia, rash, and urticaria. Even with pre-medication, severe reactions, including cytokine release syndrome, have been reported following ofatumumab use. In cases of severe infusion reaction, the infusion of ofatumumab must be interrupted immediately and symptomatic treatment instituted. Infusion reactions occur more frequently on the first day of infusion and tend to decrease with subsequent infusions. Patients with a history of decreased pulmonary function may be at a greater risk for pulmonary complications from severe reactions and should be monitored closely during infusion of ofatumumab. The safety of, and ability to generate a primary or anamnestic response to, immunization with live attenuated or inactivated vaccines during treatment with ofatumumab has not been studied.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $47.35 USD -0.11

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GSK.
View Industry Companies

Industry Analysis


Industry Average

Valuation GSK Industry Range
No financial data is available for GSK.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at